GLP-1 Coverage: Yearly Trends for Weight Loss 2024
- The increasing prevalence of obesity is driving interest in glucagon-like peptide-1 receptor agonists (GLP-1 RA) as a pharmacological treatment option.
- Despite the promise of GLP-1 drugs in addressing obesity, access remains a key issue.
- Data indicates that abandonment rates for patients approved for GLP-1 use remained steady between 2021 and 2022,at roughly 23%.
Discover crucial trends in GLP-1 coverage for weight loss, and understand the evolving landscape of obesity treatment in 2024. Obesity is projected to impact 1 billion people globally by 2030,driving the need for effective solutions,like GLP-1 receptor agonists (primarykeyword). Though, access to these potentially life-changing medications faces challenges. Patient abandonment rates and out-of-pocket costs for GLP-1 (secondarykeyword) prescriptions present key hurdles. News Directory 3’s analysis reveals vital insights into payer coverage, revealing how these factors impact patients. Explore the latest data on rejection rates, prior authorization timelines, and the shifts in patient costs. What steps are necessary to improve access and patient outcomes? Discover what’s next for GLP-1 treatments.
Payer Coverage Trends and Access to GLP-1 Drugs for Weight loss
Updated May 29, 2025
The increasing prevalence of obesity is driving interest in glucagon-like peptide-1 receptor agonists (GLP-1 RA) as a pharmacological treatment option. By 2023, the Centers for Disease Control and Prevention (CDC) reported that over a third of adults in 23 states were obese. Global projections estimate that 1 billion people will be living with obesity by 2030.
Despite the promise of GLP-1 drugs in addressing obesity, access remains a key issue. While payer coverage appears to be gradually increasing, patient abandonment rates and out-of-pocket costs continue to pose challenges. Cost is one potential reason why patients do not pick up their medication, but further research is needed.
Data indicates that abandonment rates for patients approved for GLP-1 use remained steady between 2021 and 2022,at roughly 23%. Though, in 2023, this rate climbed to 28.5%. Although the rate decreased to 17.3% in 2024, the data only covered through early October.
A slight decrease in patient out-of-pocket costs for both approved and reversed claims was observed. This analysis did not include a comprehensive breakdown of all patient assistance programs but was intended to provide a high-level view of costs.
Pull-through rates for both rejections and prior authorizations steadily increased from 16.3% in 2021 to 25.1% in 2023, before slightly declining to 24.3% in 2024. On average, it took 7.19 days to overcome a rejection, with a median of 6 days. Overcoming a prior authorization rejection took an average of 8.07 days, with a median of 7 days.
What’s next
Continued monitoring of payer policies and further research into patient access barriers are needed to fully understand the impact on obesity prevalence in the United States. Future studies should also examine trends in patient claims for associated comorbidities.